ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1267

Epidemology, Clinical Features and Relationship to Biological Therapy of Uveitis in Axial Spondyloarthritis: Single Center University Study

Iñigo Gonzalez-Mazon1, Lara Sanchez-Bilbao 2, Javier Rueda-Gotor 3, DAVID MARTINEZ-LOPEZ 4, DIANA PRIETO- PENA 1, Mónica Calderón-Goercke 5, Jose Luis Martín-Varillas 2, Belén Atienza-Mateo 2, Miguel A Gonzalez-Gay 2 and Ricardo Blanco 2, 1Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 2Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 5Hospital Marqués de Valdecilla, Santander, Cantabria, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Biologic agents and axial spondyloarthritis, Uveitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Uveitis is one of the most frequent extra articular manifestation of spondyloarthritis (SpA). Biological therapy, especially monoclonal TNF inhibitors, are useful to prevent and to treat refractory non-infectious uveitis. However, other biologics had been related to paradoxical uveitis. Our aim was to assess a) the epidemiological and clinical features of uveitis associated to SpA and b) its relationship with biological treatment used in SpA.

Methods: We set up an observational study of patients who developed uveitis form a cohort of 255 consecutive unselected patients with axial SpA (axSpA) classified according to the ASAS criteria. They were divided into: a) ankylosing spondylitis (AS) according to New York modified criteria (n= 193) b) non-radiographic axSpA (nr-axSpA) (n= 62). All these patients were followed in a single reference University Hospital.

Results: We studied 255 patients with axSpA axSpA (151 men / 104 women); mean age 37.8 ± 10.6 years. In 36 (14.2%) patients at least one episode of uveitis was observed after a follow-up 12.4 ± 4.5 years. The underlying axSpA diseases were AS (n=31) and nr-axSpA (n= 5). The mean age at onset of uveitis was 45.7±14.2 years. Uveitis was diagnosed in 5 patients before SpA diagnosis. In the remaining patients (n=31) it was detected after a median of 6 [2-15] years of follow-up after SpA diagnosis. Pattern of uveitis was anterior and acute in all cases, and unilateral in 83%. None of them presented intermediate or posterior uveitis. Median of anterior chamber cells was 1 [1-2] cells. Comparison of baseline characteristics and clinical features between patients who developed uveitis and those who did not is shown in Table 1. Almost all patients who developed uveitis were HLAB27 positive. In these patients a lower frequency of enthesitis and inflammatory bowel disease was observed. 

Cumulative incidence of uveitis episodes related to each biological agent is shown in Table 2. Patients treated with secukinumab developed 2.72 episodes of uveitis/100 patients/year, meanwhile those who received monoclonal anti TNF presented 2.53 episodes/100 patients / year.

Conclusion: The most frequent clinical pattern of uveitis in patients with SpA was acute unilateral anterior uveitis which appeared in most patients after 6 years of follow-up. Almost all of them were HLA B27 positive. No differences were found in cumulative incidence between secukinumab and monoclonal anti-TNF.


Disclosure: I. Gonzalez-Mazon, None; L. Sanchez-Bilbao, None; J. Rueda-Gotor, None; D. MARTINEZ-LOPEZ, None; D. PRIETO- PENA, None; M. Calderón-Goercke, None; J. Martín-Varillas, None; B. Atienza-Mateo, None; M. Gonzalez-Gay, Abbvie, 2, 5, 8, Celgene, 5, 8, Janssen, 2, MSD, 2, 5, 8, Pfizer, 5, 8, Roche, 2, 5, 8, Sanofi, 5, 8, Sobi, 5, 8; R. Blanco, None.

To cite this abstract in AMA style:

Gonzalez-Mazon I, Sanchez-Bilbao L, Rueda-Gotor J, MARTINEZ-LOPEZ D, PRIETO- PENA D, Calderón-Goercke M, Martín-Varillas J, Atienza-Mateo B, Gonzalez-Gay M, Blanco R. Epidemology, Clinical Features and Relationship to Biological Therapy of Uveitis in Axial Spondyloarthritis: Single Center University Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/epidemology-clinical-features-and-relationship-to-biological-therapy-of-uveitis-in-axial-spondyloarthritis-single-center-university-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemology-clinical-features-and-relationship-to-biological-therapy-of-uveitis-in-axial-spondyloarthritis-single-center-university-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology